Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Helps Makena With Statement Against High-Volume Compounding

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says it could take enforcement action against pharmacies producing large quantities of the preterm birth drug and physicians should prescribe an approved drug before a compounded version.

You may also be interested in...



Cheap Drugs Create Quality Temptations, FDA Official Says

FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.

Cheap Drugs Create Quality Temptations, FDA Official Says

FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.

Bankrupt KV Pharma’s Hopes For Makena Rest With Skeptical Judge

During a hearing in the company’s lawsuit against FDA, a federal judge repeatedly questions her authority to require the agency take enforcement action against compounding pharmacies; KV filed for bankruptcy protection three days earlier, citing its inability to realize full value of the pre-term birth drug due to competition from cheaper compounded versions of 17-P.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel